1 of 1
Story summary
- The World Health Organization (WHO) criticized a US-funded hepatitis B vaccine trial in Guinea-Bissau as unethical for withholding a vaccine.
- Danish researchers led the trial, randomizing about 14,000 newborns to birth or six weeks.
- The hepatitis B vaccine has prevented mother-to-child transmission in 70–95% of cases for over 30 years.
- Public outrage prompted the Guinea-Bissau government to suspend the trial, and the WHO plans birth-dose introduction by 2028.
